A Randomized Trial of MDMA-Assisted Cognitive-Behavioural Conjoint Therapy (CBCT) Versus CBCT in Dyads in Which One Member Has Posttraumatic Stress Disorder (PTSD)

Status: Recruiting
Location: See location...
Intervention Type: Drug, Behavioral
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

This study aims to evaluate the safety, feasibility, acceptability, and effectiveness of MDMA-assisted Cognitive-Behavioral Conjoint Therapy (CBCT) versus CBCT alone for the treatment of Post-Traumatic Stress Disorder (PTSD). PTSD is a debilitating condition that significantly impacts interpersonal relationships and the functioning of individuals and their loved ones. There is also a well-established reciprocal relationship between interpersonal relationships, PTSD, and recovery. CBCT is a manualized treatment for PTSD that simultaneously addresses PTSD symptoms and relationship satisfaction. It provides dyads with behavioral tools to navigate PTSD-related challenges, as well as the knowledge behind PTSD and how it impacts relationships. Previous research has demonstrated the efficacy of CBCT in improving PTSD symptoms, partner functioning, and relationship satisfaction in both distressed and non-distressed dyads. MDMA is a drug commonly used recreationally that has been increasingly studied because of its ability to reduce the impact of PTSD symptoms. The effects of MDMA are reduced fear, enhanced communication, trust and introspection, and increased empathy and compassion. The effects of MDMA create a state that enhances the positive effects of therapy by increasing the ability to tolerate negative emotions and allowing clients to stay engaged in therapy without being overwhelmed by the intense emotions surrounding the memories of traumatic events. It is believed that MDMA may help promote the effects of CBCT due to its ability to induce empathy and interpersonal openness. This randomized study is the second study designed to explore the efficacy of combining MDMA-assisted therapy with CBCT. This study will enroll 30 dyads, where one individual has symptoms of PTSD. Participants will undergo a 7-week psychotherapy course, in MDMA-assisted CBCT or CBCT alone. In the MDMA-assisted CBCT, participants will go through CBCT sessions, and two doses of MDMA will be used as an adjunct to psychotherapy. Participants assigned to the CBCT-only condition will go through CBCT sessions and will have the opportunity to crossover and receive the two MDMA sessions after follow-up. The primary goal of this research is to contribute to the literature on MDMA-assisted CBCT by investigating its feasibility, safety, acceptability, and effectiveness, and by comparing it to active PTSD treatments.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: t
View:

• Participant with PTSD

⁃ Meet criteria for PTSD

⁃ Have a close other person who is able and willing to participate in this study

⁃ Are at least 18 years old

⁃ Are a resident of Ontario and live within the Greater Toronto Area (GTA)

⁃ Are in good physical health

⁃ Are proficient in speaking and reading English

⁃ Are willing to have all visits audio and video recorded

⁃ Are able to swallow pills

‣ Agree to all study rules and commit to all medical and therapy visits

‣ If in psychotherapy, are willing to allow the study therapists to communicate directly with your therapist

‣ Are willing to stop taking psychiatric medications, herbal supplements, prescription and nonprescription medications during the study

‣ Agree to stay overnight on two separate occasions after each full-day MDMA-Assisted Therapy Session, and not to drive for at least 24 hours after taking MDMA

‣ Are not pregnant and will commit to not becoming pregnant during the study, if you are able to become pregnant

‣ Have a supportive relative, spouse, close friend or other caregiver not participating in this study who can serve as your emergency contact

‣ Agree to inform the researchers within 48 hours of any medical conditions and procedures

‣ Agree to not participate in any other clinical trials during this study

• Close Significant Other

‣ Have a close other person who meets criteria for PTSD and is able and willing to participate in this study

⁃ Are at least 18 years old

⁃ Are a resident of Ontario and live within the Greater Toronto Area (GTA)

⁃ Are in good physical health

⁃ Are proficient in speaking and reading English

⁃ Are willing to have all visits audio and video recorded

⁃ Are able to swallow pills

⁃ Agree to all study rules and commit to all medical and therapy visits

⁃ If in psychotherapy, are willing to allow the study therapists to communicate directly with your therapist

‣ Are willing to stop taking psychiatric medications, herbal supplements, prescription and nonprescription medications during the study

‣ Agree to stay overnight on two separate occasions after each full-day MDMA-Assisted Therapy Session, and not to drive for at least 24 hours after taking MDMA

‣ Are not pregnant and will commit to not becoming pregnant during the study, if you are able to become pregnant

‣ Have a supportive relative, spouse, close friend or other caregiver not participating in this study who can serve as your emergency contact

‣ Agree to inform the researchers within 48 hours of any medical conditions and procedure

‣ Agree to not participate in any other clinical trials during this study

Locations
Other Locations
Canada
Remedy Institute
RECRUITING
Toronto
Contact Information
Primary
Song Ge
research@remedyinstitute.ca
4372914747
Backup
Anne Wagner, C.Psych.
dr.wagner@remedyinstitute.ca
647-362-8822
Time Frame
Start Date: 2024-11-15
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 60
Treatments
Experimental: MDMA-Assisted CBCT Condition
Dyads will undergo a 7-week course of CBCT psychotherapy for PTSD with two sessions that integrate MDMA-assisted psychotherapy. MDMA will be administered in two separate sessions and integrated into the psychotherapy protocol. The two doses of MDMA during this study will be used as an adjunct to psychotherapy.
Active_comparator: CBCT-Only Condition
Dyads will undergo a 7-week course of CBCT psychotherapy for PTSD. Dyads who have undergone the CBCT-Only condition will have the option to do a crossover and have the two MDMA sessions after follow-up.
Related Therapeutic Areas
Sponsors
Collaborators: Remedy Institute
Leads: Remedy

This content was sourced from clinicaltrials.gov